Module 7
Mitochondria in Disease
Mitochondrial dysfunction is implicated in an expanding catalogue of human disease. The primary mitochondrial diseases (combined prevalence ~1 in 4 300) are among the most common inherited metabolic disorders. Beyond these monogenic syndromes, mitochondrial dysfunction is increasingly recognised as a common mechanistic thread running through neurodegeneration, cardiovascular disease, diabetes, cancer, immune dysregulation, and aging itself. This module reviews the genetic principles, canonical syndromes, and the mitochondrial contribution to complex common disease.
Video: Mitochondrial Metabolism & Cell Decisions
A seminar-style treatment of how metabolic state — NAD+/NADH ratio, acetyl-CoA availability, TCA intermediates, membrane potential — drives cell-fate decisions from proliferation to apoptosis. Directly sets up the disease mechanisms covered below.
1. Heteroplasmy & the Threshold Effect
Each cell contains 100–1 000 mtDNA copies. When a mutation arises, it occupies a fraction of that pool — the cell is now heteroplasmic (mixture of wildtype and mutant) rather than homoplasmic. Below a tissue-specific threshold (often 60–90%), wildtype mtDNA produces enough functional protein to compensate; above threshold, respiratory capacity collapses and phenotype emerges sharply.
Mathematically the threshold is a sigmoid rather than a strict cliff, reflecting the nonlinear relation between enzyme level and flux (metabolic control analysis, Rossignol 2003). Complex IV reserve is particularly high: 65–75% of complex IV activity can be lost before respiration slows.
The germline bottleneck. During oogenesis, primordial germ cells retain only ~200 mtDNA segregating units from a population of many thousands. Stochastic resampling at this bottleneck means offspring of a low-heteroplasmy mother can inherit anywhere from 0% to >90% mutant mtDNA — explaining the dramatic variability of mitochondrial disease within a single matriline (Wai et al. 2008).
High-demand tissues first. Brain, heart, retina, cochlea, and skeletal muscle are metabolically demanding and have low thresholds (70–85%); skin and blood tolerate much higher loads (>95%). This pattern explains the stereotyped “neuromuscular” phenotype of most primary mitochondrial disease — and why diagnostic muscle biopsy can show ragged-red fibres while blood mtDNA looks almost normal.
Simulation: Threshold & Bottleneck
Click Run to execute the Python code
Code will be executed with Python 3 on the server
2. Canonical Primary Mitochondrial Syndromes
Leigh syndrome
Subacute necrotising encephalomyelopathy. Infant-onset regression after a normal first year — loss of head control, dystonia, respiratory irregularity. Pathognomonic MRI: bilateral basal-ganglia and brainstem hyperintensity (periaqueductal grey, substantia nigra). >80 genetic causes identified, spanning mtDNA (m.8993T>G ATP6, complex I subunits) and nuclear genes (SURF1, NDUFS4, SDHA). Median survival ~3 years; no disease-modifying treatment to date. Recent AAV gene therapy trials for NDUFS4-Leigh are encouraging in mouse models (Di Meo 2017).
MELAS
Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like episodes. ~80% of cases carry the m.3243A>G mutation in mtDNA tRNA-Leu(UUR), disrupting mitochondrial translation. Childhood-to-young-adult onset of migrainous headaches, seizures, and non-vascular-territory stroke-like episodes with cortical lesions that cross arterial boundaries. Elevated lactate on MR spectroscopy. Treatment is supportive; intravenous L-arginine during acute episodes improves endothelial function; taurine supplementation restores tRNA taurinylation (approved in Japan 2019).
LHON (Leber Hereditary Optic Neuropathy)
Sudden bilateral central visual loss in young adults — often sequentially, weeks apart. Affects retinal-ganglion-cell (RGC) axons in the papillomacular bundle, which have particularly dense mitochondrial content. Three mutations account for ~95% of cases: m.11778G>A (ND4), m.3460G>A (ND1), m.14484T>C (ND6) — all complex I. Strong male penetrance (~50% of male carriers, ~10% of female) with partial X-linked modifier loci. LHON was the first mitochondrial disease treated with gene therapy: intravitreal AAV-ND4 (Lumevoq, GenSight) improved vision in m.11778G>A carriers (REVERSE/RESCUE trials 2020).
Kearns-Sayre syndrome (KSS) & CPEO
Single large mtDNA deletions (typically 2–10 kb), usually sporadic. Progressive external ophthalmoplegia (CPEO) alone is mild; KSS adds onset before age 20, pigmentary retinopathy, and cardiac conduction block — a cardiac-pacemaker indication. Deletion heteroplasmy varies by tissue, highest in muscle (ragged-red fibres on modified Gomori trichrome; COX-negative fibres on histochemistry).
MERRF
Myoclonic Epilepsy with Ragged-Red Fibres. >80% carry m.8344A>G mtDNA tRNA-Lys. Myoclonus, generalised epilepsy, cerebellar ataxia, and proximal myopathy. Onset childhood to early adulthood. Reduced mitochondrial translation produces multi-complex deficiency on muscle biopsy.
NARP & MILS
m.8993T>G in mtDNA ATP6 (complex V a-subunit). Low heteroplasmy (~70%) produces NARP: Neuropathy, Ataxia, Retinitis Pigmentosa. High heteroplasmy (>90%) in the same family produces MILS: Maternally Inherited Leigh Syndrome. The parent-child allelic dosage shift is often the clearest classroom demonstration of the threshold effect.
Nuclear-encoded syndromes
The majority of childhood mitochondrial disease is nuclear-encoded: mutations in OxPhos assembly factors (SURF1, SCO2, BCS1L), mtDNA-maintenance genes (POLG, TWINKLE, TYMP, DGUOK), iron-sulphur cluster biogenesis (ISCU, friedreich ataxia FXN), mitochondrial translation (EFG1, MRPL44), and import machinery (TIMM8A — Mohr-Tranebjaerg syndrome). Inheritance is Mendelian. Whole-exome sequencing now yields molecular diagnosis in ~60% of suspected paediatric mitochondrial disease (Wortmann 2015).
3. Neurodegeneration
Parkinson’s disease.The MPTP story (Langston 1983) — a contaminant of street-drug synthesis producing rapid-onset parkinsonism in young users — established complex-I inhibition as sufficient to recapitulate the disease. Postmortem substantia nigra shows complex-I deficiency. Monogenic PD genes converge on mitochondrial quality control: PINK1 and Parkin mediate mitophagy (M6);DJ-1 is a redox sensor; LRRK2 regulates mitochondrial dynamics; CHCHD2 is an IMS protein. Dopaminergic neurons are uniquely vulnerable: long unmyelinated axons, pacemaker Ca2+ cycling that taxes mitochondrial buffering, and aerobic metabolism of dopamine into ROS-generating quinones.
Alzheimer’s disease.Early metabolic abnormality: FDG-PET shows reduced glucose uptake in posterior cingulate and parietal cortex years before clinical dementia. Cybrid cell experiments (Swerdlow & Khan 2004) demonstrated that Alzheimer’s-derived mtDNA transferred into rho-zero (mtDNA-depleted) cells transfers respiratory deficits — the “mitochondrial-cascade hypothesis”. Abeta peptide localises to mitochondria via TOM translocase and inhibits complex IV; phospho-tau impairs trafficking via KIF5B. Mitochondrial biogenesis agonists (bezafibrate, resveratrol) are in trial as disease-modifiers.
Huntington’s disease.Mutant huntingtin binds outer mitochondrial membrane, impairs axonal transport (Miro/TRAK complex, M6), and reduces PGC-1α transcription — suppressing biogenesis. Striatal medium spiny neurons have the lowest mitochondrial reserve of any forebrain population, matching disease topology.
ALS. SOD1 mutations cause mitochondrial-matrix SOD1 aggregates, disrupting IMM architecture. TDP-43 and C9orf72 pathologies also converge on mitochondrial dysfunction. Motor-neuron mitochondria show distinctive vacuolisation on electron microscopy even before symptom onset.
4. Cancer & the Warburg Effect
Otto Warburg (1931 Nobel) observed that tumour cells ferment glucose to lactate even in the presence of oxygen — aerobic glycolysis. He proposed defective mitochondria as cancer’s root cause. Modern view (Vander Heiden, Cantley & Thompson 2009): Warburg metabolism is not about ATP yield but about biosynthesis. Glycolytic intermediates feed the pentose-phosphate pathway (nucleotide synthesis), serine/glycine biosynthesis, and macromolecular precursors. Rapidly dividing cells need building blocks more than they need ATP.
Crucially, tumour mitochondria remain functional and are often essential for tumour progression: TCA-cycle-derived aspartate is rate-limiting for proliferation (Sullivan 2015); electron transport is required for de novo pyrimidine synthesis via DHODH (complex III upstream of ubiquinone). Mitochondrial biogenesis is elevated in chemotherapy-resistant cancer stem cells. This has driven renewed interest in mitochondria-targeted cancer therapy: IACS-010759 (complex I inhibitor, Phase I trials), CPI-613 (PDH/α-KGDH inhibitor), metformin repurposing, and BH3-mimetic venetoclax (already approved) which triggers mitochondrial apoptosis in CLL/AML.
Oncometabolites. Germline/somatic mutations in TCA enzymes (SDHA-D, FH, IDH1/2) produce paragangliomas, leiomyomas, and gliomas. Mutant IDH generates 2-hydroxyglutarate, which inhibits α-KG–dependent dioxygenases, globally rewiring DNA and histone methylation. Ivosidenib (IDH1) and enasidenib (IDH2) are approved for mutant-IDH AML.
5. Heart Failure & Cardiac Disease
Cardiomyocyte mitochondria occupy ~30% of cell volume and turn over the cellular ATP pool every ~10 seconds. Failing human heart shows down-regulation of OxPhos genes, mtDNA depletion, decreased PGC-1α, and shift towards ketone-body oxidation — the failing heart burns ketones preferentially (Bedi 2016), the rationale for SGLT2-inhibitor benefit in HFrEF (Verma 2018).
Ischaemia-reperfusion (I/R).During reperfusion, accumulated succinate is rapidly oxidised via complex II running in reverse, generating a ROS burst that opens the mitochondrial permeability transition pore (mPTP) and kills cardiomyocytes (Chouchani 2014). Dimethyl malonate (competitive succinate inhibitor) is cardioprotective in animal models.
Mitochondrial cardiomyopathies.TAZ mutations (Barth syndrome) disrupt cardiolipin remodelling. ANT1 mutations cause autosomal dominant CPEO with cardiomyopathy. Doxorubicin cardiotoxicity is mitochondrial: topoisomerase-2β–mediated mtDNA damage.
6. Metabolic & Immune Disease
Type 2 diabetes. Insulin-resistant muscle and liver exhibit reduced mitochondrial content and impaired OxPhos flux (Petersen & Shulman 2004). Whether this is cause or consequence is debated; PGC-1α agonism and exercise both improve both insulin sensitivity and mitochondrial biogenesis.
NAFLD/MASH. Hepatic mitochondrial dysfunction drives lipid accumulation and oxidative injury. Resmetirom (FDA 2024) and future mitochondrial-uncoupler candidates (mitochondria-targeted dinitrophenol derivatives) address this axis.
Innate immunity. Circulating mtDNA released from damaged tissue acts as a DAMP via TLR9 and cGAS-STING, driving sterile inflammation. Cardiolipin, leaked mtDNA, and formyl peptides are evolutionary echoes of bacterial origin (M1) — the immune system treats mitochondrial contents like invading bacteria. Chronic mtDNA cytosolic leak contributes to inflammatory aging (“inflammaging”), lupus flares, and rheumatoid arthritis.
7. Mitochondria & Aging
Harman’s 1956 “free-radical theory of aging” proposed that mitochondrial ROS damage is the engine of senescence. The simple version is wrong — antioxidant supplementation does not extend lifespan and can shorten it — but the refined version (Mitochondrial Free Radical Theory, Barja 2013) holds: low-level ROS signals adaptively, while high-level damage accumulates as mtDNA mutations, lipid peroxidation (4-HNE), and protein carbonylation.
Polg mutator mouse (Trifunovic 2004).A proof-reading-deficient mtDNA polymerase γ accelerates mtDNA point-mutation accumulation. These mice age prematurely — kyphosis, greying, sarcopenia, cardiomyopathy — at ~9 months, establishing mtDNA mutation as a sufficient cause of aging phenotypes in mammals.
Clonal expansion. In post-mitotic tissue (neurones, cardiomyocytes, muscle fibres), a single mtDNA mutation can clonally expand within a cell over decades, eventually producing “mosaic” COX-negative fibres scattered through aged muscle and heart. mtDNA deletion clones are particularly expansion-prone because the shorter molecule replicates faster (the “survival of the smallest” hypothesis, Kowald & Kirkwood 2014).
Mitochondrial aging is one of the original hallmarks of aging (Lopez-Otin 2013, 2023). Interventions that improve mitochondrial quality — caloric restriction, exercise, rapamycin, NAD+ precursors (NR, NMN), urolithin A — all extend healthspan or lifespan in model organisms and are under human trial.
Simulation: Age-Related mtDNA Accumulation
Click Run to execute the Python code
Code will be executed with Python 3 on the server
8. Diagnosis
The modern diagnostic pathway has shifted dramatically with next-generation sequencing. Traditionally: lactate/pyruvate ratio, urine organic acids, muscle biopsy with respiratory-chain enzymology and histochemistry (ragged-red fibres on Gomori trichrome, COX-negative fibres, SDH hyperactivity), electron microscopy (paracrystalline inclusions, abnormal cristae).
Today: first-line is panel or whole-exome sequencing of nuclear-encoded mitochondrial genes (>1 500 nuclear genes plus the 37-gene mtDNA), with long-range PCR for mtDNA deletions. Diagnostic yield ~60% with WES, higher with combined WES + mtDNA + transcriptomics. Functional validation via fibroblast respirometry (Seahorse extracellular flux) remains important for VUS interpretation.
Key References
• Gorman, G. S. et al. (2016). “Mitochondrial diseases.” Nat. Rev. Dis. Primers, 2, 16080.
• DiMauro, S. & Schon, E. A. (2003). “Mitochondrial respiratory-chain diseases.” N. Engl. J. Med., 348, 2656–2668.
• Wai, T., Teoli, D. & Shoubridge, E. A. (2008). “The mitochondrial DNA genetic bottleneck results from replication of a subpopulation of genomes.” Nat. Genet., 40, 1484–1488.
• Trifunovic, A. et al. (2004). “Premature ageing in mice expressing defective mitochondrial DNA polymerase.” Nature, 429, 417–423.
• Valente, E. M. et al. (2004). “Hereditary early-onset Parkinson’s disease caused by mutations in PINK1.” Science, 304, 1158–1160.
• Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. (2009). “Understanding the Warburg effect.” Science, 324, 1029–1033.
• Chouchani, E. T. et al. (2014). “Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS.” Nature, 515, 431–435.
• Lopez-Otin, C. et al. (2023). “Hallmarks of aging: an expanding universe.” Cell, 186, 243–278.
• Yu-Wai-Man, P. et al. (2020). “Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy.” Sci. Transl. Med., 12, eaaz7423.